STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS | Dr Hirotoshi Watanabe

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

Dr. Hirotoshi Watanabe (Kyoto University Graduate School of Medicine, JP) discusses the results of the STOPDAPT-2 ACT study. The aim of this study was to assess the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
The trial showed that In ACS patients who underwent successful PCI using CoCr-EES, clopidogrel monotherapy after 1-month DAPT failed to attest the noninferiority to 12-month DAPT with aspirin and clopidogrel for the net clinical benefit with a trend toward increase in cardiovascular events despite reduction in major bleeding events.

Discussion Points:
-Importance of the study
-Key methods and results
-Impact on practice
-Applicability to populations outside of Japan

Recorded remotely from Tokyo, 2021.

Editor: Mirjam Boros

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.